AP546A - Peptides for inhibiting pepsin release. - Google Patents

Peptides for inhibiting pepsin release. Download PDF

Info

Publication number
AP546A
AP546A APAP/P/1995/000724A AP9500724A AP546A AP 546 A AP546 A AP 546A AP 9500724 A AP9500724 A AP 9500724A AP 546 A AP546 A AP 546A
Authority
AP
ARIPO
Prior art keywords
pro
thr
gln
lys
val
Prior art date
Application number
APAP/P/1995/000724A
Other versions
AP9500724A0 (en
Inventor
Monique Descroix-Vagne
Danielle Pansu
Thierry Tarrade
Original Assignee
Soc De Conseils De Recherches Et Dapplications Scientifiques S C R A S
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soc De Conseils De Recherches Et Dapplications Scientifiques S C R A S, Inst Nat Sante Rech Med filed Critical Soc De Conseils De Recherches Et Dapplications Scientifiques S C R A S
Publication of AP9500724A0 publication Critical patent/AP9500724A0/en
Application granted granted Critical
Publication of AP546A publication Critical patent/AP546A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Peptides derived from the c terminal sequence of sorbin, but containing at least one d-amino acid residue, inhibit pepsin release and are therefore likely to be useful in the treatment of ulcers or oesophagitis. Their salts and substitution derivatives are also claimed as a pharmaceutical compositions containing them.

Description

The invention relates to peptides able to inhibit the release of pepsin, to substitution derivatives and salts of such peptides and to pharmaceutical compositions containing these peptides. The peptides may be of use in the treatment of diseases related to the release of pepsin, and more particularly the treatment of ulcers or oesophagitis.
A new peptide has recently been isolated from pig intestines; this peptide, known as sorbin, has 153 natural amino acids (WO 89/06241). Sorbin and its C terminal peptide fragments (up to 40 amino acid residues) are able to provoke an increase in the process of absorption by the mucosa. We have unexpectedly found that the modification of these peptide fragments by the insertion of at least one D-amino acid residue confers another biological activity on these modified peptide analogues: they inhibit the release of pepsin, £ a biological activity which unmodified peptides do not have. •'r
This activity is particularly interesting in certain circumstances. Gastric digestion is the result of the action of enzymes, hydrochloric acid and pepsin. Pepsin is a protein; with gastrin, it is also one of the main constituents of the gastric juice. Its main physiological 15 role is the initiation of protein digestion. However, many studies have shown the significant role of pepsin in the formation of ulcers. Consequently, in certain circumstances it may be desirable to inhibit the release of pepsin at least in part
The invention provides a peptide of the general formula I
A [ A2 Aj 2 I in which:
Ai represents the residue L-Thr or D-Thr; or one of the following sequences in which at least one amino acid residue may be of D configuration:
Val-Thr,
BAD ORIGINAL Q
- 2Pro-Val-Thr,
Arg-Pro-Val-Thr,
Glu-Arg-Pro-Val-Thr,
His-Glu-Arg-Pro-Val-Thr,
Gln-His-Glu-Arg-Pro-Val-Thr,
Leu-Gln-His-Glu-Arg-Pro-Val-Thr,
Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr,
Ser-Ile-Leu-Gin-His-Glu-Arg-Pro-Val-Thr,
Ser-Ser-lle-Leu-Gln-His-Glu-Arg-Pro-Val-Thr,
Lys-Ser-Ser-lie-Leu-Gln-His-Glu-Arg-Pro-Val-Thr,
Gly-Lys-Ser-Ser-lie-Leu-Gln-His-Glu-Arg-Pro-Val-Thr,
Pro-Gly-Lys-Ser-Ser-lie-Leu-Gln-His-Glu-Arg-Pro-Val-Thr or Glu-Pro-Gly-Lys-Ser-Ser-lie-Leu-Gin-His-Glu-Arg-Pro-Val-Thr;
A2 represents the sequence Lys-Pro-Gln-AJa in which at least one amino acid residue may be of D configuration;
A3 represents a covalent bond or the sequence Gly-Ag-As in which each of A4 and A5 independently represents a basic amino acid residue; and
X represents a hydroxy, amino or alkylamino group; with the proviso that the peptide contains at least one D-amino acid residue.
The invention also provides substitution derivatives of the peptides of the general formula I in which one or more of the amino acid residues is substituted by a protecting group or protecting groups conventionally employed in peptides intended for biological use; when there are two or more protecting groups, they need not be the same. Preferably, the protecting groups are selected from lower alkyl, such as methyl or t-butyl; phenyl; benzyl or substituted benzyl such as trimethoxybenzyl; 2-chlorobenzyloxycarbonyl; 9-fluorenylmethyloxycarbonyl (Fmoc); t-butoxycarbonyl (Boc); acetyl; sulphonyl; and phosphoryl groups.
The invention further provides peptides containing the amino acid sequence A1-A2-A3, in which Ai, A2 and A3 are as defined above.
The invention yet further provides pharmaceutically acceptable salts of peptides as defined above. These salts may be obtained with organic acids such as acetic, lactic, pamoic, maleic, citric, malic, ascorbic, benzoic, salicylic, succinic, methylsulphonic and
AP-'F; 95/00721
BAD ORIGINAL
AP.00546
-3toluenesulphonic acids; mineral acids such as hydrochloric , sulphuric or phosphoric acids; or polymeric acids such as tannic acid or carboxymethyl cellulose.
Each of A4 and A5, when present in peptides according to the invention, preferably independently represents a Lys, D-Lys, Arg or D-Arg residue.
As noted above, the peptides according to the invention contain one or more D-amino acid residues. When there is one, it is preferably the N terminal residue or the C terminal residue. When there are two, one is preferably the C terminal residue; the other may be located at any position, but is preferably the N-terminal residue. The preferred peptides are those in which A2 represents Lys-Pro-Gln-D-Ala and A3 represents a covalent bond.
Preferred substitution derivatives of the peptides include those in which Lys residues bear acetyl protecting groups.
Examples of the preferred peptides according to the invention are the following:
Thr-Lys-Pro-Gln-D-Ala-NH2,
Thr-Lys-Pro-Gln-D-Ala-Gly-Lys-Lys-NH2,
Thr-(acetyl)Lys-Pro-Gln-D-Ala-NH2,
Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH2,
Pro-D-Val-Thr-Lys-Pro-Gln-Ala-NH2,
Pro-Val-Thr-Lys-Pro-Gln-Ala-Gly-Arg-D-Arg, Pro-Val-Thr-(acetyl)Lys-Pro-Gln-D-Ala-NH2.
D-Pro-Val-Thr-Lys-Pro-Gln-Ala-NH2,
His-Glu-Arg-Pro- V al-Thr-Lys-Pro-Gln-D- Ala-NH2, Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH2, Glu-Pro-Gly-Lys-Ser-Ser-Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr-Lys-Pro-Gln-D-AlaNH2,
D-Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH2,
D-Pro-Val-Thr-Lys-Pro-Gln-Ala-Gly-D-Lys-Lys-NH2, Pro-D-Val-Thr-Lys-Pro-Gln-D-Ala-NH2 and D-Pro-Val-Thr-(acetyl)Lys-Pro-Gln-D-Ala-NH2.
The peptides according to the invention may be prepared by any of the conventional peptide synthesis methods. For example, they may advantageously be prepared by solid phase synthesis carried out as follows: the formation of the peptide chain begins with the fixing of the C terminal amino acid of the chain via its carboxy group to a resin; the amino function is protected with a protecting group such as Boc. After fixing the C terminal to
O') . 0 . <0 l«o
BAD ORIGINAL
-4amino acid to the resin, its amine function is deprotected by washing the resin with an acid. In the case of protection with Boc, deprotection can take place by washing with trifluoroacetic acid. The second amino acid, the amine function of which is protected, is then coupled via its carboxy group to the deprotected amino function of the C terminal amino acid of the chain. This coupling preferably takes place in the presence of a coupling agent such as dicyclohexylcarbodiimide or diisopropylcarbodiimide. The peptide chain thus formed comprises two amino acids, the end amine function of which is protected. As before, this end amine function is deprotected and the fixing of the third amino acid can take place. The desired peptide chain is thus obtained by fixing the amino acids one after the other. After elimination of all the protecting groups, the peptide is detached from the resin.
The synthesis of a peptide of the invention, Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH2, is described briefly below. Other peptides of the invention can be prepared by suitable modifications of this peptide synthesis.
The synthesis is carried out in the solid phase at ambient temperature. The method used X?
comprises the following stages: deprotection, neutralisation and coupling. The resin used is of the cross-linked polystyrene type with 1% divinyl benzene (Merrifield resin). BocD-Ala is fixed to the Merrifield resin in the presence of caesium carbonate in toluene and dimethylformamide (DMF). The terminal amine function of the amino acids used is protected by the Boc group. These Boc groups are displaced by trifluoroacetic acid ~ _ CL' followed by several washings with dichloromethane and isopropanol. The amino groups are neutralised with triethylamine followed by several washings. The threonine and valine are transformed before coupling into an ester of hydroxybenzotriazole in the presence of ic
Ik.
diisopropylcarbodiimide (DIPCDI); for glutamine, the ester of hydroxybenzotriazole is ' formed directly in the reactor. The lysine and the two prolines are transformed into symmetrical anhydride before coupling. In all cases, coupling takes place in the presence of diisopropylethyiamine. The side chain of the lysine is protected by an Fmoc grouping, whereas that of the threonine is not protected. On completion of the last coupling, the Fmoc grouping is displaced by piperidine in DMF before displacement of the Boc protecting group from the N terminal amine function of the proline. The peptide is obtained by cleavage of the resin after treatment in ammonia in a methanol/DMF mixture.
The crude product thus obtained is then purified.
The invention additionally provides a pharmaceutical composition comprising a peptide of the general formula I as defined above, a substitution derivative of such a peptide as
BAD ORIGINAL &
AP .0 0 5 4 6
-5defined above or a peptide including the amino acid sequence A1-A2-A3 as defined above, in admixture with a pharmaceutically acceptable diluent or carrier.
The peptides of the invention can be administered by the oral, intravenous, parenteral, subcutaneous, intraperitoneal or intramuscular routes.
The pharmaceutical composition may take the form of a capsule, a tablet, a lyophilate or a liquid depending on the method of administration selected. The pharmaceutical composition may also take the form of a prolonged release formulation.
By the oral route, peptides according to the invention may be administered in man at a dose of 5 to 100 gg/kg per day. By the intravenous or subcutaneous route, peptides according to the invention may be administered in man at a dose of 1 to 12 gg/kg one to three times per day. In the animal, the preparations according to the invention are found in large quantities in the organism several days after one acute administration, and more particularly the peptide Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH2 which is found in quantities greater than 10%.
Toxicity
The subacute toxicity was studied in the rat and the dog. Following administrations of doses up to 4000 gg/kg/d, no sign of toxicity and no signs suggesting a mutagenic power were observed four weeks after administration. In man, a subcutaneous or intravenous injection at the dose of 200 gg/kg causes no biological, clinical or pathological anomaly.
Pharmacology
The therapeutical interest of the peptides of the invention has been established by the following experiment.
The intensity of the gastric response is measured by determining the volume of gastric secretion induced.
Cats were operated on under general anaesthetic; the operation allowed the stomach to be divided into two parts: Heidenheim's pouch and the gastric fistula. These two pouches are diverted to the outside in order to recover the secretions of hydrochloric acid, pepsin and gastric juices, once during the basal phase and then after stimulation. These cats have chronic fistulas: they can therefore undergo a number of tests each week and be their own controls. The secretion of pepsin is stimulated by administration to the living animals of
AP/P/ 9 5 / 0 0 7 2 4
BAD ORIGINAL
-6pentagastrin (PG) and VIP (Vasoactive Intestinal Peptide) by perfusion for 2 hours at the rate of 2 and 4 pg/kg/h.
One hour after stimulation by pentagastrin and VIP, these peptides were added in perfusion at the dose of 100 pmol/kg/h. The volume of gastric juices was collected over the 30 minutes preceding perfusion until the end of perfusion. The quantity of pepsin in the gastric juice (as homogeneous as possible) was evaluated by a proteolytic spectrophotometric method.
The results obtained in 9 to 12 experiments are reported in the Tables below; the secretion of pepsin is expressed in mg/15 minutes, mean of 2 periods of 15 minutes per test during the basal secretion and mean of 6 periods of 15 minutes during the stimulated secretion.
Certain peptides of the invention with at least one D-amino acid residue are compared with their analogues in which all the amino acid residues are of L configuration.
AP/P/ 9 5/0072^
BAD ORIGINAL
AP . Ο Ο 5 4 6
-7TABLEl
Comparison of the activity of a peptide of the invention PDt: Pro-Val-Thr-Lys-Pro-GlnD-Ala-NH2.
with that of its analogue 5 Pi: Pro-Val-Thr-Lys-Pro-Gln-Ala-NH2
VIP + PG VIP + PG + Pl VIP + PG + PD1
Cat No 1 1.775 0.952 0.926
Cat No 2 1.316 1.367 1.711
Cat No 3 2.049 1.680 1.846
Cat No 1 1.852 2.993 2.082
Cat No 2 3.334 2.418 2.157
Cat No 3 4.010 5.392 3.932
Cat No 1 2.520 1.729 1.456
Cat No 2 2.409 2.403 1.516
Cat No 3 4.277 3.989 3.891
Cat No 1 1.750 - -
Cat No 2 1.556 - -
Cat No 3 4.442 - -
Mean 2.607 2.547 2.169
Std Dev 0.323 0.468 0.351
' z L 0 0 I S S /d/dV
BAD ORIGINAL
-8TABLE2
Activity of the peptides of the invention PD2 : D-Pro-Val-Thr-Lys-Pro-Gln-Ala-NH2,
Pd3 : Pro-Val-Thr-(acetyl)Lys-Pro-Gln-D-Ala-NH2
PD4: D-Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH2
VIP + PG VIP + PG + Pd2 VIP + PG + Pd3 VIP + PG + P°4
Cat no 1 6.727 2.689 2,317 4,427
Cat no 2 4.773 2.007 1,860 2,999
Cat no 3 4.324 2.576 0,891 2,898
Cat no 4 2.458 2.076 1,725 3,780
Cat no 5 3.744 2.689 2,630 3,740
Cat no 6 3.276 1.143 2,217 3,147
Cat no 7 2.708 2.409 1,899 2,452
Cat no 8 3.991 3.172 4,321 3,996
Cat no 9 0.384 1.036 0,738 0,236
Cat no 10 5.184 3.164 3,811 3,362
Mean 3.757 2.296** 2.241** 3,104**
Std Dev 0.544 0.235 0,358 0,368
>2/00/56 Zd/dV bad original
PDs: Pro-D-Val-Thr-Lys-Pro-Gln-Ala-NH2,
Pd6 : Pro-D-Val-Thr-Lys-Pro-Gln-D-Ala-NH2
Pd7 : D-Pro-Val-Thr-(acetyl)Lys-Pro-GIn-D-Ala-NH2
TABLE 3
Activity of the peptides of the invention
VIP + PG VIP + PG + Pd5 VIP + PG + P°6 VIP + PG + Ρθ7
Cat No 1 6.727 4.263 2.480 2.163
Cat No 2 4.773 2.435 2.544 2.995
Cat No 3 4.324 1.317 2.589 1.441
Cat No 4 2.458 3.191 3.110 2.834
Cat No 5 3.744 2.727 4.142 1.236
Cat No 6 3.276 3.486 1.710 2.047
Cat No 7 2.708 2.634 2.370 2.544
Cat No 8 3.991 2.852 4.165 3.971
Cat No 9 0.384 1.132 1.693 1.520
Cat No 10 5.184 3.804 2.931 3.402
Mean 3.757 2.784 2.773 2.415
Std Dev 0.544 0.315 0.270 ' 0.284
BAD ORIGINAL £
- 10TABLE4
Activity of the peptides of the invention
Pd8 : His-Glu-Arg-Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH2
Ρθ9 : Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH2
PDio: Glu-Pro-Gly-Lys-Ser-Ser-Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr-Lys-Pro-GlnD-Ala-NH2·
VIP + PG VIP + PG + PD8 VIP + PG + P°9 VIP + PG + PDio
Cat no 1 3.832 3.117 2.409 2.691
Cat no 2 1.826 2.730 1.440 1.764
Cat no 3 2.132 1.690 1.964 2.520
Cat no 4 3.891 1.725 2.259 2.410
Cat no 5 2.042 2.076 1.230 2.833
Cat no 6 3.250 1.358 1.580 2.877
Cat no 7 4.014 2.452 2.488 1.726
Cat no 8 4.280 2.689 2.426 2.015
Cat no 9 3.273 2.920 3.790 1.953
Mean 3.171 2.306* 2.176* 2.310*
Std Dev 0.313 0.206 0.254 0.151
AP/P/ 9 5 / 0 0 7 2·
BAD ORIGINAL CT
AP . Ο Ο 5 4 6
- 11 TABLE 5
Comparison of the activity of a peptide of the invention
PDg: His-Glu-Arg-Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH2 with that of its analogue
Pg His-Glu-Arg-Pro-Val-Thr-Lys-Pro-Gln-Ala-NH2
VIP + PG VIP + PG + Ps VIP + PG + P°R
Cat no 1 4.385 3.693 2.717
Cat no 2 4.460 4.915 4.630
Cat no 3 3.079 3.350 2.198
Cat no 4 3.333 2.442 1.746
Cat no 1 3.410 3.896 2.270
Cat no 2 2.510 2.432 2.245
Cat no 3 2.764 1.626 2.452
Cat no 4 2.191 1.925 2.247
Cat no 5 4.908 5.012 2.739
Mean 3.449 3.255 2.583*
Std Dev 0.314 0.412 0.274
ζ ο o /56 /<T'civ
BAD ORIGIN*1- £$
- 12 TABLE 6
Activity of the peptides of the invention
PDn : Thr-Lys-Pro-Gln-D-Ala-NH2 P°i2: Thr-(acetyl)Lys-Pro-Gln-D-Ala-NH2
VIP + PG VIP + PG + PDu VIP + PG + P°12
Cat no 1 3.217 3.452 2.620
Cat no 2 3.772 3.114 1.925
Cat no 3 3.580 3.348 4.037
Cat no 4 2.166 2.181 1.896
Cat no 5 6.562 2.219 3.585
Cat no 6 2.290 1.638 2.192
Cat no 7 2.008 3.291 0.625
Cat no 8 2.034 2.076 1.339
Cat no 9 2.548 0.850 1.385
Mean 3.131 2.463 2.178*
Std Dev 0.484 0.299 0.364

Claims (19)

  1. C LAI MS
    1. A peptide of the general formula I
    Aj Aj Α^ Z I in which:
    5 Ai represents the residue L-Thr or D-Thr; or one of the following sequences in which at least one amino acid residue may be of D configuration:
    Val-Thr,
    C Pro-Val-Thr,
    Arg-Pro-Val-Thr,
    10 Glu-Arg-Pro-Val-Thr,
    His-Glu-Arg-Pro-Val-Thr,
    Gln-His-Glu-Arg-Pro-Val-Thr,
    Leu-Gln-His-Glu-Arg-Pro-val-Thr,
    Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr,
    15 Ser-Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr,
    Ser-Ser-Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr,
    Lys-Ser-Ser-Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr, Gly-Lys-Ser-Ser-lle-Leu-Gln-His-Glu-Arg-Pro-Val-Thr, θ Pro-Gly-Lys-Ser-Ser-Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr or
    20 Glu-Pro-Gly-Lys-Ser-Ser-lle-Leu-Gln-His-Glu-Arg-Pro-Val-Thr;
    o
    A2 represents the sequence Lys-Pro-Gln-Ala in which at least one amino acid residue may be of D configuration;
    A3 represents a covalent bond or the sequence Gly-A4-A5 in which each of A4 and A5 independently represents a basic amino acid residue; and
    25 X represents a hydroxy, amino or alkylamino group; with the proviso that the peptide contains at least one D-amino acid residue.
  2. 2. A peptide containing the amino acid sequence Ai-A2-A3, in which Aj, A2 and A3 are as defined in claim 1, the peptide containing at least one D-amino acid residue.
    Z 0 0 / s 6 /d/dV
    BAD ORIGINAL
    - 14CA
  3. 3. A substitution derivative of a peptide according to claim 1 or 2 in which one or more of the amino acid residues is substituted by a protecting group or protecting groups conventionally employed in peptides intended for biological use; when there are two or more protecting groups, they need not be the same.
  4. 5 4. A peptide according to claim 3 containing at least one acetyl protected lysine residue.
    5. A peptide according to any preceding claim in the form of its pharmaceutically acceptable salt
  5. 6. A peptide according to any preceding claim in which the C-terminal amino acid 10 residue is of D-configuration.
  6. 7. A peptide according to any preceding claim in which the N-terminal amino acid residue is of D-configuration.
  7. 8. A peptide according to any preceding claim in which A2 represents Lys-Pro-Gln-DAla and A3 represents a covalent bond.
    15
  8. 9. A peptide of the formula
    Thr-Lys-Pro-Gln-D-Ala-NH2.
  9. 10. A peptide of the formula Thr-Lys-Pro-Gln-D-Ala-Gly-Lys-Lys-NH2·
  10. 11. A peptide of the formula
    20 Thr-(acetyl)Lys-Pro-Gln-D-Ala-NH2.
  11. 12. A peptide of the formula
    Pro-V al-Thr- Lys- Pro-G ln-D- Ala- NH2.
  12. 13. A peptide of the formula Pro-D-Val-Thr-Lys-Pro-Gln-Ala-NH2.
    25
  13. 14. A peptide of the formula
    Pro-Val-Thr-Lys-Pro-Gln-Ala-Gly-Arg-D-Arg.
  14. 15. A peptide of the formula Pro-Val-Thr-(acetyl)-Lys-Pro-Gln-D-Ala-NH2.
    AP/P/ 95/0072*
    BAD ORIGINAL
    AP . Ο Ο 5 4 6
    - 1516. A peptide of the formula D-Pro-Val-Thr-Lys-Pro-Gln-Ala-NH2.
  15. 17. A peptide of the formula His-Glu-Arg-Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH2.
    5
  16. 18. A peptide of the formula
    Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH2.
  17. 19. A peptide of the formula Glu-Pro-Gly-Lys-Ser-Ser-Ile-Leu-Gln-His-Glu-Arg-ProVal-Thr-Lys-Pro-Gln-D-Ala-NH2.
    c
  18. 20. A peptide of the formula , 10 D-Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH2.
  19. 21. A peptide of the formula D-Pro-Val-Thr-Lys-Pro-Gln-Ala-Gly-D-Lys-Lys-NH22 2. A peptide of the formula Pro-D-Val-Thr-Lys-Pro-Gln-D-Ala-NH2·
    15 23. A peptide of the formula
    D-Pro-Val-Thr-(acetyl)Lys-Pro-Gln-D-Ala-NH224. A pharmaceutical composition comprising a peptide according to any preceding claim in admixture with a pharmaceutically acceptable diluent or carrier.
APAP/P/1995/000724A 1994-03-16 1995-03-09 Peptides for inhibiting pepsin release. AP546A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9405162A GB9405162D0 (en) 1994-03-16 1994-03-16 Heptapeptides

Publications (2)

Publication Number Publication Date
AP9500724A0 AP9500724A0 (en) 1995-04-30
AP546A true AP546A (en) 1996-10-29

Family

ID=10751970

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1995/000724A AP546A (en) 1994-03-16 1995-03-09 Peptides for inhibiting pepsin release.

Country Status (31)

Country Link
US (1) US5668109A (en)
EP (1) EP0750635B1 (en)
JP (1) JP3109835B2 (en)
KR (1) KR100359713B1 (en)
CN (1) CN1070865C (en)
AP (1) AP546A (en)
AT (1) ATE174037T1 (en)
AU (1) AU694476B2 (en)
BR (1) BR9507063A (en)
CA (1) CA2144569A1 (en)
DE (1) DE69506390T2 (en)
DK (1) DK0750635T3 (en)
DZ (1) DZ1865A1 (en)
ES (1) ES2127516T3 (en)
FI (1) FI963615A0 (en)
FR (2) FR2717391B1 (en)
GB (2) GB9405162D0 (en)
GR (1) GR3029513T3 (en)
IE (1) IE950192A1 (en)
MA (1) MA23481A1 (en)
NO (1) NO316802B1 (en)
NZ (1) NZ270704A (en)
OA (1) OA10136A (en)
PL (1) PL180672B1 (en)
RO (1) RO112729B1 (en)
RU (1) RU2144038C1 (en)
TN (1) TNSN95019A1 (en)
TW (1) TW380141B (en)
UA (1) UA55369C2 (en)
WO (1) WO1995025123A1 (en)
ZA (1) ZA951923B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405162D0 (en) * 1994-03-16 1994-04-27 Scras Heptapeptides
TW201318665A (en) * 2011-11-03 2013-05-16 San Huei United Co Ltd Foldable 3D mask

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2298334A1 (en) * 1975-01-21 1976-08-20 Merck & Co Inc CHEMICAL PROCESSES AND PRODUCTS
WO1989006241A1 (en) * 1988-01-08 1989-07-13 Institut National De La Sante Et De La Recherche M Sorbin and peptide derivatives which increase aborption by the mucous membranes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601020B1 (en) * 1986-07-03 1989-05-12 Inst Nat Sante Rech Med PURIFIED SORBIN, NOVEL PEPTIDES HAVING PEPTIDE SEQUENCES IN COMMON WITH SORBIN AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
PT93320B (en) * 1990-03-02 1996-07-31 Univ Tulane PROCESS FOR THE PREPARATION OF THERAPEUTIC PEPTIDEES
GB9405162D0 (en) * 1994-03-16 1994-04-27 Scras Heptapeptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2298334A1 (en) * 1975-01-21 1976-08-20 Merck & Co Inc CHEMICAL PROCESSES AND PRODUCTS
WO1989006241A1 (en) * 1988-01-08 1989-07-13 Institut National De La Sante Et De La Recherche M Sorbin and peptide derivatives which increase aborption by the mucous membranes

Also Published As

Publication number Publication date
NO963856L (en) 1996-09-13
GB9405162D0 (en) 1994-04-27
AU694476B2 (en) 1998-07-23
AU1487095A (en) 1995-09-28
RU2144038C1 (en) 2000-01-10
FR2717390A1 (en) 1995-09-22
GR3029513T3 (en) 1999-05-28
GB2287942A (en) 1995-10-04
KR970701732A (en) 1997-04-12
UA55369C2 (en) 2003-04-15
GB2287942B (en) 1997-07-16
FR2717390B1 (en) 1996-05-31
FI963615A (en) 1996-09-13
OA10136A (en) 1996-12-18
CA2144569A1 (en) 1995-09-17
MA23481A1 (en) 1995-10-01
WO1995025123A1 (en) 1995-09-21
ZA951923B (en) 1995-12-11
EP0750635A1 (en) 1997-01-02
BR9507063A (en) 1997-09-02
PL180672B1 (en) 2001-03-30
TNSN95019A1 (en) 1996-02-06
FR2717391A1 (en) 1995-09-22
CN1070865C (en) 2001-09-12
DE69506390T2 (en) 1999-07-01
CN1143968A (en) 1997-02-26
JPH09512787A (en) 1997-12-22
ES2127516T3 (en) 1999-04-16
NO963856D0 (en) 1996-09-13
JP3109835B2 (en) 2000-11-20
RO112729B1 (en) 1997-12-30
KR100359713B1 (en) 2003-01-15
IE950192A1 (en) 1995-09-20
ATE174037T1 (en) 1998-12-15
FR2717391B1 (en) 1996-05-31
NZ270704A (en) 1996-05-28
DE69506390D1 (en) 1999-01-14
TW380141B (en) 2000-01-21
EP0750635B1 (en) 1998-12-02
FI963615A0 (en) 1996-09-13
AP9500724A0 (en) 1995-04-30
NO316802B1 (en) 2004-05-18
DZ1865A1 (en) 2002-02-17
MX9603991A (en) 1997-09-30
DK0750635T3 (en) 1999-08-16
PL316288A1 (en) 1997-01-06
GB9504733D0 (en) 1995-04-26
US5668109A (en) 1997-09-16

Similar Documents

Publication Publication Date Title
US4737487A (en) VIP type peptides
JPH0314599A (en) Peptide derivatives
IE47380B1 (en) Novel cyclopeptides
HU211603A9 (en) Nonapeptide bombesin antagonists
US4866039A (en) Peptides containing the 18 to 23 residues of vasoactive intestinal peptide, and analogues
AU641366B2 (en) Peptide compounds
US4631270A (en) Therapeutically useful pseudopeptides, compositions containing the same and methods of preparation and use
EP0353565A1 (en) Immunostimulating peptides, a process for their preparation and pharmaceutical commpositions containing them
HU181843B (en) Process for producing acth derivatives of psichopharmacological activity
DK149113B (en) METHOD OF ANALOGUE FOR THE PREPARATION OF AN ACTH DERIVATIVE CONTAINING FROM 10 TO 21 AMINO ACID ACID OR PHARMACOLOGICALLY ACCEPTABLE SALTS OR METAL COMPLEXES THEREOF
AP546A (en) Peptides for inhibiting pepsin release.
US3488726A (en) R-l-methionyl-glycyl octapeptides related to caerulein and intermediates therefor
EP0101929B1 (en) Polypeptide-diesters, their production and use
DK164875B (en) GONADOLIBERIN DERIVATIVES AND THEIR PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALTS OR METAL COMPLEXES, A PROCEDURE FOR PREPARING THEM AND A PHARMACEUTICAL PREPARATION CONTAINING THESE
JPH0730112B2 (en) Novel pseudopeptide compound with bradykinin antagonism
EP0132919A1 (en) Peptides
US4474765A (en) Biologically active peptides
US3812091A (en) D-analogs of secretin
MXPA96003991A (en) Peptides to inhibit the release of peps
JPS6136298A (en) Tripeptideamides
NZ220561A (en) Cholecystokinin derivatives
GB2118190A (en) Peptides with sauvagine-like activity
JPS6330499A (en) Opioid peptide-polypeptide complex
EP0463070A1 (en) A process for producing pentapeptides and intermediates for use in the synthesis.
CS199674B2 (en) Method of producing polypeptides